(Q36020658)

English

Initiating oral glucose-lowering therapy with metformin in type 2 diabetic patients: an evidence-based strategy to reduce the burden of late-developing diabetes complications

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

11 August 2017

1 reference

Europe PubMed Central

Initiating oral glucose-lowering therapy with metformin in type 2 diabetic patients: an evidence-based strategy to reduce the burden of late-developing diabetes complications (English)

1 reference

Europe PubMed Central

PubMed publication ID

11 August 2017

1 reference

based on heuristic

inferred from title

complications of diabetes mellitus

1 reference

based on heuristic

inferred from title

author name string

Consoli A

1

1 reference

Europe PubMed Central

PubMed publication ID

11 August 2017

Gomis R

2

1 reference

Europe PubMed Central

PubMed publication ID

11 August 2017

Halimi S

3

1 reference

Europe PubMed Central

PubMed publication ID

11 August 2017

Home PD

4

1 reference

Europe PubMed Central

PubMed publication ID

11 August 2017

Mehnert H

5

1 reference

Europe PubMed Central

PubMed publication ID

11 August 2017

Strojek K

6

1 reference

Europe PubMed Central

PubMed publication ID

11 August 2017

Van Gaal LF

7

1 reference

Europe PubMed Central

PubMed publication ID

11 August 2017

publication date

1 December 2004

1 reference

Europe PubMed Central

PubMed publication ID

11 August 2017

Diabetes and Metabolism

1 reference

Europe PubMed Central

PubMed publication ID

11 August 2017

30

1 reference

Europe PubMed Central

PubMed publication ID

11 August 2017

6

1 reference

Europe PubMed Central

PubMed publication ID

11 August 2017

509-516

1 reference

Europe PubMed Central

PubMed publication ID

11 August 2017

Diabetes trends in Europe

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970148-9

7 January 2021

based on heuristic

inferred from DOI database lookup

The projected health care burden of Type 2 diabetes in the UK from 2000 to 2060.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970148-9

7 January 2021

based on heuristic

inferred from DOI database lookup

The rising prevalence of diabetes and impaired glucose tolerance: the Australian Diabetes, Obesity and Lifestyle Study

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970148-9

7 January 2021

based on heuristic

inferred from DOI database lookup

High prevalence of type 2 diabetes in all ethnic groups, including Europeans, in a British inner city: relative poverty, history, inactivity, or 21st century Europe?

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970148-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Undiagnosed diabetes mellitus among patients with prior myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970148-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Prevalence, predictors, and consequences of unrecognized diabetes mellitus in 3266 patients scheduled for coronary angiography

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970148-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Impaired glucose tolerance and impaired fasting glycaemia: the current status on definition and intervention

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970148-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Screening for type 2 diabetes and impaired glucose metabolism: the Australian experience

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970148-9

7 January 2021

based on heuristic

inferred from DOI database lookup

A Danish diabetes risk score for targeted screening: the Inter99 study

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970148-9

7 January 2021

based on heuristic

inferred from DOI database lookup

The performance of a risk score as a screening test for undiagnosed hyperglycemia in ethnic minority groups: data from the 1999 health survey for England

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970148-9

7 January 2021

based on heuristic

inferred from DOI database lookup

The diabetes risk score: a practical tool to predict type 2 diabetes risk

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970148-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term improvement in insulin sensitivity by changing lifestyles of people with impaired glucose tolerance: 4-year results from the Finnish Diabetes Prevention Study

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970148-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970148-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970148-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970148-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term (5-year) effects of a reduced-fat diet intervention in individuals with glucose intolerance

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970148-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970148-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Pathophysiology of type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970148-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Cross-sectional and prospective associations between proinsulin and cardiovascular disease risk factors in a population experiencing rapid cultural transition

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970148-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of withdrawal from metformin on the development of diabetes in the diabetes prevention program

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970148-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970148-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970148-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Diabetic macrovascular disease: the glucose paradox?

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970148-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Quality of life in type 2 diabetic patients is affected by complications but not by intensive policies to improve blood glucose or blood pressure control (UKPDS 37). U.K. Prospective Diabetes Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970148-9

7 January 2021

based on heuristic

inferred from DOI database lookup

The significant effect of diabetes duration on coronary heart disease mortality: the Framingham Heart Study

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970148-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Impact of diabetes duration and cardiovascular risk factors on mortality in type 2 diabetes: the Hoorn Study

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970148-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Oral antidiabetic treatment in patients with coronary disease: time-related increased mortality on combined glyburide/metformin therapy over a 7.7-year follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970148-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970148-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Study rationale and design of ADVANCE: action in diabetes and vascular disease--preterax and diamicron MR controlled evaluation

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970148-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Preventing type II diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970148-9

7 January 2021

based on heuristic

inferred from DOI database lookup

A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970148-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970148-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970148-9

7 January 2021

based on heuristic

inferred from DOI database lookup

XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970148-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970148-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Inside guidelines: comparative analysis of recommendations and evidence in diabetes guidelines from 13 countries

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970148-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study).

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970148-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970148-9

7 January 2021

based on heuristic

inferred from DOI database lookup

The Diabetes Prevention Program: baseline characteristics of the randomized cohort. The Diabetes Prevention Program Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970148-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Carbohydrate nutrition, insulin resistance, and the prevalence of the metabolic syndrome in the Framingham Offspring Cohort

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970148-9

7 January 2021

based on heuristic

inferred from DOI database lookup

The 1997 American Diabetes Association criteria versus the 1985 World Health Organization criteria for the diagnosis of abnormal glucose tolerance: poor agreement in the Hoorn Study.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970148-9

7 January 2021

based on heuristic

inferred from DOI database lookup

The metabolic syndrome as predictor of type 2 diabetes: the San Antonio heart study

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970148-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Worldwide experience of metformin as an effective glucose-lowering agent: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970148-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy of metformin in the treatment of NIDDM. Meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970148-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Metformin: an antihyperglycemic agent for treatment of type II diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970148-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of metformin in pediatric patients with type 2 diabetes: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970148-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Type 2 diabetes in children and adolescents. American Diabetes Association

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970148-9

7 January 2021

based on heuristic

inferred from DOI database lookup

National Surveillance for Type 2 Diabetes Mellitus in Taiwanese Children

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970148-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Type 2 diabetes in Asian-Indian urban children

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970148-9

7 January 2021

based on heuristic

inferred from DOI database lookup

[Early detection of diabetics in Munich 1967-68]

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970148-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Type 2 diabetes mellitus in UK children--an emerging problem.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970148-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Type 2 diabetes mellitus in children and adolescents: a review from a European perspective

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970148-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970148-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970148-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970148-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Miglitol combined with metformin improves glycaemic control in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970148-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Nateglinide improves glycaemic control when added to metformin monotherapy: results of a randomized trial with type 2 diabetes patients

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970148-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Rationale and options for combination therapy in the treatment of Type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970148-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970148-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Improved glycaemic control with metformin-glibenclamide combined tablet therapy (Glucovance) in Type 2 diabetic patients inadequately controlled on metformin

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970148-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Improved glycaemic control by addition of glimepiride to metformin monotherapy in type 2 diabetic patients

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970148-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Simultaneous glyburide/metformin therapy is superior to component monotherapy as an initial pharmacological treatment for type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970148-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Gastrointestinal tolerability of extended-release metformin tablets compared to immediate-release metformin tablets: results of a retrospective cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970148-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970148-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Risk of Fatal and Nonfatal Lactic Acidosis With Metformin Use in Type 2 Diabetes Mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970148-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1262-3636(07)70148-9

1 reference

Europe PubMed Central

PubMed publication ID

11 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

11 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36020658&oldid=1628836013"